Trial Profile
A Pharmacodynamic Study Using NaF PET/CT Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Metastatic Castrate Resistant Prostate Cancer to Bone
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Orteronel (Primary)
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Therapeutic Use
- 20 Jul 2017 Status changed from active, no longer recruiting to discontinued because Study supporter (Takeda) ended study drug for prostate cancer; enrollment ended prematurely.
- 17 Jun 2016 Planned End Date changed from 1 May 2016 to 1 Dec 2016.
- 26 Feb 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 May 2015 to 1 Sep 2014.